Its Friday! Since most of our news consumption consists of bad news, especially during this time with a pandemic, rioting, protests, murder hornets, alcoholic killer monkeys, meth gators, and squirrels carrying the Bubonic Plague.
Its Friday! Since most of our news consumption consists of bad news, especially during this time with a pandemic, rioting, protests, murder hornets, alcoholic killer monkeys, meth gators, and squirrels carrying the Bubonic Plague.
Today, Canadian Blood Servicesand Canadas COVID-19 Immunity Task Force (CITF)are releasing initial results of the first 10,000 blood donor samples assessed for SARS-CoV-2 antibodies. This analysis reveals that over the period May 9 through June 8, 2020, fewer than 1 per cent of the 10,000 samples from blood donors tested positive for antibodies to the novel coronavirus
On July 24, the Food and Drug Administration (FDA) granted accelerated approval of a new CAR-T therapy, Tecartus (brexucabtagene autoleucel), for adults with mantle cell lymphoma who have not responded to or who have relapsed after other kinds of treatment. Tecartus (formerly known as KTE-X19), manufactured by Kite, a Gilead Company, is a living drug that reprograms a patients own T cells to fight cancer. About two thirds of participants treated in the ZUMA-2 study experienced complete remission, which in a majority of cases lasted at least a year.
Science and research have always relied on using animals to understand various human diseases. The primarily reasons have been the genetic similarity between animals and humans (mice share 98% of DNA with us), and that we have developed tools to edit genes in various animals.
Abstract More than 1050 clinical trials are registered at FDA.gov that explore multipotent mesenchymal stromal cells (MSCs) for nearly every clinical application imaginable, including neurodegenerative and cardiac disorders, perianal fistulas, graft-versus-host disease, COVID-19, and cancer.
Ooops... Error 404 Sorry, but the page you are looking for doesn't exist
R3 International is now including exosomes with its stem cell therapy program in Mexico for autism. They have been shown to be an effective, safe option for autism patients. SCOTTSDALE, Ariz., July 23, 2020 /PRNewswire-PRWeb/ --R3 International is now including exosomes with its stem cell therapy program in Mexico for autism
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters. According to Global Stem Cell Therapy Market Report, by Cell Source (Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells, and Others), by Application (Musculoskeletal Disorders, Wounds and Injuries, Cancer, Autoimmune Disorders, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), published by Coherent Market Insights, the global stem cell therapy market was valued at US$ 7,313.6 million in 2018, and is expected to exhibit a CAGR of 21.1% over the forecast period (2019-2027). Increasing incidence of spinal cord injuries is expected to boost growth of the global stem cell therapy market over the forecast period
This post was contributed by a community member. Celltex Therapeutics hosts webinar on life-changing mesenchymal stem cell banking and therapy Webinar to be hosted Wednesday, July 29 WHAT: Celltex Therapeutics, a Houston-based biotechnology company, will host a free virtual webinar Wednesday, July 29, 2020 about the benefits of utilizing your own mesenchymal stem cells (MSCs) and how they can lead to proven results and an improved quality of life.
Goosebumps are a weird quirk of our bodies that science doesnt fully understand. Now, researchers at Harvard have uncovered a biological reason for the reaction: its our bodies way of stimulating stem cells to drive new hair growth. Were all familiar with goosebumps
Recent Comments